Published in Nat Rev Microbiol on May 14, 2012
Evolutionary medicine: its scope, interest and potential. Proc Biol Sci (2012) 1.94
How can mathematical models advance tuberculosis control in high HIV prevalence settings? Int J Tuberc Lung Dis (2014) 1.49
Whole-genome-based Mycobacterium tuberculosis surveillance: a standardized, portable, and expandable approach. J Clin Microbiol (2014) 1.41
Patients are paying too much for tuberculosis: a direct cost-burden evaluation in Burkina Faso. PLoS One (2013) 1.31
Human genetics of tuberculosis: a long and winding road. Philos Trans R Soc Lond B Biol Sci (2014) 1.25
A medicinal chemists' guide to the unique difficulties of lead optimization for tuberculosis. Bioorg Med Chem Lett (2013) 1.25
Can combination prevention strategies reduce HIV transmission in generalized epidemic settings in Africa? The HPTN 071 (PopART) study plan in South Africa and Zambia. J Acquir Immune Defic Syndr (2013) 1.23
Global epidemiology of tuberculosis. Cold Spring Harb Perspect Med (2014) 1.11
Bayesian models leveraging bioactivity and cytotoxicity information for drug discovery. Chem Biol (2013) 1.10
Latent tuberculosis infection: myths, models, and molecular mechanisms. Microbiol Mol Biol Rev (2014) 1.06
Tuberculosis: From an incurable scourge to a curable disease - journey over a millennium. Indian J Med Res (2013) 1.01
TB Mobile: a mobile app for anti-tuberculosis molecules with known targets. J Cheminform (2013) 0.98
Functional drug screening reveals anticonvulsants as enhancers of mTOR-independent autophagic killing of Mycobacterium tuberculosis through inositol depletion. EMBO Mol Med (2014) 0.94
Design, synthesis and anti-tuberculosis activity of 1-adamantyl-3-heteroaryl ureas with improved in vitro pharmacokinetic properties. Bioorg Med Chem (2013) 0.93
Morphological characterization of Mycobacterium tuberculosis in a MODS culture for an automatic diagnostics through pattern recognition. PLoS One (2013) 0.92
microRNA-146a promotes mycobacterial survival in macrophages through suppressing nitric oxide production. Sci Rep (2016) 0.92
Translational Research for Tuberculosis Elimination: Priorities, Challenges, and Actions. PLoS Med (2016) 0.92
Physiology, Biochemistry, and Applications of F420- and Fo-Dependent Redox Reactions. Microbiol Mol Biol Rev (2016) 0.87
New drugs to treat multidrug-resistant tuberculosis: the case for bedaquiline. Ther Clin Risk Manag (2014) 0.86
Antibacterial activity of and resistance to small molecule inhibitors of the ClpP peptidase. ACS Chem Biol (2013) 0.86
A multi-antigenic adenoviral-vectored vaccine improves BCG-induced protection of goats against pulmonary tuberculosis infection and prevents disease progression. PLoS One (2013) 0.86
The cytochrome bd-type quinol oxidase is important for survival of Mycobacterium smegmatis under peroxide and antibiotic-induced stress. Sci Rep (2015) 0.84
Lessons from Africa: developing a global human rights framework for tuberculosis control and prevention. BMC Int Health Hum Rights (2014) 0.84
Anti-tuberculosis lead molecules from natural products targeting Mycobacterium tuberculosis ClpC1. J Ind Microbiol Biotechnol (2015) 0.83
Structure and inhibition of tuberculosinol synthase and decaprenyl diphosphate synthase from Mycobacterium tuberculosis. J Am Chem Soc (2014) 0.82
Barriers to completing TB diagnosis in Yemen: services should respond to patients' needs. PLoS One (2014) 0.82
Long-acting antituberculous therapeutic nanoparticles target macrophage endosomes. FASEB J (2014) 0.81
A distinct MaoC-like enoyl-CoA hydratase architecture mediates cholesterol catabolism in Mycobacterium tuberculosis. ACS Chem Biol (2014) 0.80
Tuberculosis disease diagnosis using artificial immune recognition system. Int J Med Sci (2014) 0.79
Helicobacter hepaticus infection in BALB/c mice abolishes subunit-vaccine-induced protection against M. tuberculosis. Vaccine (2015) 0.79
Mycobacterium tuberculosis DinG is a structure-specific helicase that unwinds G4 DNA: implications for targeting G4 DNA as a novel therapeutic approach. J Biol Chem (2014) 0.78
Mycobacterium tuberculosis RecG Protein but Not RuvAB or RecA Protein Is Efficient at Remodeling the Stalled Replication Forks: IMPLICATIONS FOR MULTIPLE MECHANISMS OF REPLICATION RESTART IN MYCOBACTERIA. J Biol Chem (2015) 0.78
Use of eCompliance, an innovative biometric system for monitoring of tuberculosis treatment in rural Uganda. Am J Trop Med Hyg (2015) 0.78
First insights into circulating Mycobacterium tuberculosis complex lineages and drug resistance in Guinea. Infect Genet Evol (2015) 0.78
Clinical and radiographic manifestations and treatment outcome of pulmonary tuberculosis in the elderly in khuzestan, southwest iran. Tanaffos (2014) 0.77
The Bandim TBscore--reliability, further development, and evaluation of potential uses. Glob Health Action (2014) 0.77
A tuberculosis nationwide prevalence survey in Gambia, 2012. Bull World Health Organ (2016) 0.77
Unemployment in TB patients - ten-year observation at regional center of pulmonology in Bydgoszcz, Poland. Med Sci Monit (2014) 0.77
Mycobacterial RNA isolation optimized for non-coding RNA: high fidelity isolation of 5S rRNA from Mycobacterium bovis BCG reveals novel post-transcriptional processing and a complete spectrum of modified ribonucleosides. Nucleic Acids Res (2014) 0.77
A survey to assess the extent of public-private mix DOTS in the management of tuberculosis in Zambia. Afr J Prim Health Care Fam Med (2015) 0.77
Design, development, drug-likeness, and molecular docking studies of novel piperidin-4-imine derivatives as antitubercular agents. Drug Des Devel Ther (2015) 0.76
Retracted Application status of MALDI-TOF mass spectrometry in the identification and drug resistance of Mycobacterium tuberculosis. J Thorac Dis (2014) 0.76
Radiolabelling and positron emission tomography of PT70, a time-dependent inhibitor of InhA, the Mycobacterium tuberculosis enoyl-ACP reductase. Bioorg Med Chem Lett (2015) 0.75
Incidence of tuberculosis among school-going adolescents in South India. BMC Public Health (2016) 0.75
A Perspective of the Diagnosis and Management of Congenital Tuberculosis. J Pathog (2016) 0.75
Mycobacterial Protein Tyrosine Phosphatases A and B Inhibitors Augment the Bactericidal Activity of the Standard Anti-tuberculosis Regimen. ACS Infect Dis (2015) 0.75
Diagnosing tuberculosis with a novel support vector machine-based artificial immune recognition system. Iran Red Crescent Med J (2015) 0.75
Molecular Typing of Mycobacterium Tuberculosis Strains: A Fundamental Tool for Tuberculosis Control and Elimination. Infect Dis Rep (2016) 0.75
The Berlin Declaration on tuberculosis and its consequences for TB research and control in the WHO-Euro region. Eur J Microbiol Immunol (Bp) (2012) 0.75
Study of streptomycin-induced ototoxicity: protocol for a longitudinal study. Springerplus (2016) 0.75
Knowledge and perceptions of national and provincial tuberculosis control programme managers in Pakistan about the WHO Stop TB strategy: a qualitative study. JRSM Open (2016) 0.75
Tuberculosis: finding a new potential antimycobacterium derivative in a aldehyde-arylhydrazone-oxoquinoline series. Curr Microbiol (2012) 0.75
Diagnostic accuracy of Xpert MTB/RIF assay for musculoskeletal tuberculosis: a meta-analysis. Infect Drug Resist (2017) 0.75
Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med (2010) 32.89
An outbreak of multidrug-resistant tuberculosis among hospitalized patients with the acquired immunodeficiency syndrome. N Engl J Med (1992) 18.11
Global epidemiology of tuberculosis. Morbidity and mortality of a worldwide epidemic. JAMA (1995) 15.26
Tuberculosis: commentary on a reemergent killer. Science (1992) 14.51
The emergence of drug-resistant tuberculosis in New York City. N Engl J Med (1993) 12.71
Global surveillance for antituberculosis-drug resistance, 1994-1997. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. N Engl J Med (1998) 10.78
Diabetes mellitus increases the risk of active tuberculosis: a systematic review of 13 observational studies. PLoS Med (2008) 9.31
Randomised controlled trial of self-supervised and directly observed treatment of tuberculosis. Lancet (1998) 7.72
The global tuberculosis situation and the new control strategy of the World Health Organization. Tubercle (1991) 7.70
Tuberculosis in developing countries: burden, intervention and cost. Bull Int Union Tuberc Lung Dis (1990) 7.11
Tuberculosis control and elimination 2010-50: cure, care, and social development. Lancet (2010) 7.07
Effectiveness of the direct observation component of DOTS for tuberculosis: a randomised controlled trial in Pakistan. Lancet (2001) 6.23
Drivers of tuberculosis epidemics: the role of risk factors and social determinants. Soc Sci Med (2009) 5.93
WHO's new Stop TB Strategy. Lancet (2006) 5.59
Evolution of tuberculosis control and prospects for reducing tuberculosis incidence, prevalence, and deaths globally. JAMA (2005) 5.39
Directly observed therapy and treatment adherence. Lancet (2000) 4.95
The effect of tuberculosis control in China. Lancet (2004) 4.84
Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practice. Lancet (2010) 4.71
International standards for tuberculosis care. Lancet Infect Dis (2006) 4.67
Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications. Int J Tuberc Lung Dis (1999) 4.52
Tobacco smoke, indoor air pollution and tuberculosis: a systematic review and meta-analysis. PLoS Med (2007) 4.51
Directly observed treatment of tuberculosis. We can't afford not to try it. N Engl J Med (1993) 4.47
The problem of self-administration of drugs; with particular reference to pulmonary tuberculosis. Tubercle (1958) 4.28
HIV infection-associated tuberculosis: the epidemiology and the response. Clin Infect Dis (2010) 4.19
Drug-resistant tuberculosis: review of the worldwide situation and the WHO/IUATLD Global Surveillance Project. International Union Against Tuberculosis and Lung Disease. Clin Infect Dis (1997) 4.02
HIV-associated tuberculosis in developing countries: epidemiology and strategies for prevention. Tuber Lung Dis (1992) 3.95
TUBERCULOSIS IN TROPICAL AFRICA. AN EPIDEMIOLOGICAL STUDY. Bull World Health Organ (1964) 3.90
The HIV-associated tuberculosis epidemic--when will we act? Lancet (2010) 3.82
Increasing transparency in partnerships for health--introducing the Green Light Committee. Trop Med Int Health (2002) 3.59
Tuberculosis and HIV infection in sub-Saharan Africa. JAMA (1992) 3.51
The Global Plan to Stop TB, 2006-2015. actions for life: towards a world free of tuberculosis. Int J Tuberc Lung Dis (2006) 3.47
Alcohol use as a risk factor for tuberculosis - a systematic review. BMC Public Health (2008) 3.32
Public health. Responding to market failures in tuberculosis control. Science (2001) 3.12
Assessment of worldwide tuberculosis control. WHO Global Surveillance and Monitoring Project. Lancet (1997) 3.06
The Global Fund: managing great expectations. Lancet (2004) 2.94
Evolution of WHO policies for tuberculosis control, 1948-2001. Lancet (2002) 2.84
Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnostics. Proc Natl Acad Sci U S A (2009) 2.78
A global health fund: a leap of faith? BMJ (2001) 2.70
Recent advances in epidemiological research in tuberculosis. Adv Tuberc Res (1980) 2.34
Global tuberculosis drug development pipeline: the need and the reality. Lancet (2010) 2.26
The dynamics of tuberculosis in response to 10 years of intensive control effort in Peru. J Infect Dis (2001) 2.23
Will DOTS do it? A reappraisal of tuberculosis control in countries with high rates of HIV infection. Int J Tuberc Lung Dis (1999) 2.18
New vaccines for tuberculosis. Lancet (2010) 2.14
From exposure to disease: the role of environmental factors in susceptibility to and development of tuberculosis. Epidemiol Rev (2001) 2.03
Costs and cost-effectiveness of different DOT strategies for the treatment of tuberculosis in Pakistan. Directly Observed Treatment. Health Policy Plan (2002) 1.96
Overview and epidemiologic assessment of the current global tuberculosis situation with an emphasis on control in developing countries. Rev Infect Dis (1989) 1.96
Progress in global tuberculosis control 1995-1996, with emphasis on 22 high-incidence countries. Global Monitoring and Surveillance Project. Int J Tuberc Lung Dis (1999) 1.90
The Global TB Drug Facility: innovative global procurement. Int J Tuberc Lung Dis (2004) 1.81
Lives saved by tuberculosis control and prospects for achieving the 2015 global target for reducing tuberculosis mortality. Bull World Health Organ (2011) 1.64
Tuberculosis control in resource-poor countries: have we reached the limits of the universal paradigm? Trop Med Int Health (2004) 1.55
Low access to a highly effective therapy: a challenge for international tuberculosis control. Bull World Health Organ (2002) 1.53
Public-private mix for DOTS implementation: what makes it work? Bull World Health Organ (2004) 1.46
How human immunodeficiency virus voluntary testing can contribute to tuberculosis control. Bull World Health Organ (2003) 1.43
From HIV to tuberculosis and back again: a tale of activism in 2 pandemics. Clin Infect Dis (2010) 1.42
Health-system strengthening and tuberculosis control. Lancet (2010) 1.40
Principles of IUATLD collaborative tuberculosis progammes. Bull Int Union Tuberc Lung Dis (1991) 1.38
Impact of BCG vaccination programmes in children and young adults on the tuberculosis problem. Tubercle (1976) 1.28
Health sector reform: making health development sustainable. Health Policy (1996) 1.28
New drugs and new regimens for the treatment of tuberculosis: review of the drug development pipeline and implications for national programmes. Curr Opin Pulm Med (2010) 1.27
Science and social justice: the lessons of HIV/AIDS activism in the struggle to eradicate tuberculosis. Int J Tuberc Lung Dis (2006) 1.25
Chemotherapy of pulmonary tuberculosis. Br Med J (1959) 1.22
A concurrent comparison of home and sanatorium treatment of pulmonary tuberculosis in South India. Bull World Health Organ (1959) 1.17
Association between HTLV-III/LAV infection and tuberculosis in Zaire. JAMA (1986) 1.15
Tackling poverty in tuberculosis control. Lancet (2005) 1.02
What research is needed to stop TB? Introducing the TB Research Movement. PLoS Med (2011) 0.97
Report on the meeting of the Second Ad Hoc Committee on the TB epidemic: recommendations to Stop TB Partners, Montreux, Switzerland, 18-19 September 2003. Int J Tuberc Lung Dis (2004) 0.94
Global Partnership to Stop TB: a model of an effective public health partnership. Int J Tuberc Lung Dis (2004) 0.93
Transforming the global tuberculosis response through effective engagement of civil society organizations: the role of the World Health Organization. Bull World Health Organ (2011) 0.90
WHO EXPERT COMMITTEE ON TUBERCULOSIS. EIGHTH REPORT. World Health Organ Tech Rep Ser (1964) 0.86
Disseminated tuberculosis and the acquired immunodeficiency syndrome. Ann Intern Med (1983) 0.84
Health sector reform: scourge or salvation for TB control in developing countries? Int J Tuberc Lung Dis (2000) 0.78
Epidemiology of antituberculosis drug resistance 2002-07: an updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Lancet (2009) 7.22
Tuberculosis control and elimination 2010-50: cure, care, and social development. Lancet (2010) 7.07
Drivers of tuberculosis epidemics: the role of risk factors and social determinants. Soc Sci Med (2009) 5.93
The impact of diabetes on tuberculosis treatment outcomes: a systematic review. BMC Med (2011) 4.91
Tuberculosis. N Engl J Med (2013) 4.75
Epidemiology of antituberculosis drug resistance (the Global Project on Anti-tuberculosis Drug Resistance Surveillance): an updated analysis. Lancet (2006) 4.73
International standards for tuberculosis care. Lancet Infect Dis (2006) 4.67
Latent Mycobacterium tuberculosis infection. N Engl J Med (2015) 4.62
Surveillance of anti-tuberculosis drug resistance in the world: an updated analysis, 2007-2010. Bull World Health Organ (2011) 4.19
Opportunities and challenges for HIV care in overlapping HIV and TB epidemics. JAMA (2008) 3.78
Feasibility and cost-effectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru. Lancet (2002) 3.67
Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis. PLoS Med (2012) 3.44
Improving tuberculosis control through public-private collaboration in India: literature review. BMJ (2006) 3.19
Scaling up interventions to achieve global tuberculosis control: progress and new developments. Lancet (2012) 2.83
Global epidemiology of tuberculosis: prospects for control. Semin Respir Crit Care Med (2008) 2.57
Prospects for tuberculosis elimination. Annu Rev Public Health (2012) 2.50
MDR tuberculosis--critical steps for prevention and control. N Engl J Med (2010) 2.49
Towards universal access to HIV prevention, treatment, care, and support: the role of tuberculosis/HIV collaboration. Lancet Infect Dis (2006) 2.48
Rapid molecular TB diagnosis: evidence, policy making and global implementation of Xpert MTB/RIF. Eur Respir J (2012) 2.47
Tuberculosis control in the era of HIV. Nat Rev Immunol (2005) 2.40
The association between alcohol use, alcohol use disorders and tuberculosis (TB). A systematic review. BMC Public Health (2009) 2.39
Bi-directional screening for tuberculosis and diabetes: a systematic review. Trop Med Int Health (2010) 2.38
The global fight against HIV/AIDS, tuberculosis, and malaria: current status and future perspectives. Am J Clin Pathol (2009) 2.34
Cost and cost-effectiveness of PPM-DOTS for tuberculosis control: evidence from India. Bull World Health Organ (2006) 2.31
Drug-resistant tuberculosis: time for visionary political leadership. Lancet Infect Dis (2013) 2.16
Turning liabilities into resources: informal village doctors and tuberculosis control in Bangladesh. Bull World Health Organ (2006) 2.14
Social franchising of TB care through private GPs in Myanmar: an assessment of treatment results, access, equity and financial protection. Health Policy Plan (2007) 2.03
The WHO policy package to combat antimicrobial resistance. Bull World Health Organ (2011) 1.93
XDR-TB: entering the post-antibiotic era? Int J Tuberc Lung Dis (2006) 1.86
Implementation of isoniazid preventive therapy for people living with HIV worldwide: barriers and solutions. AIDS (2010) 1.77
Engaging hospitals to meet tuberculosis control targets in China: using the Internet as a tool to put policy into practice. Bull World Health Organ (2010) 1.76
Drug-resistant tuberculosis--current dilemmas, unanswered questions, challenges, and priority needs. J Infect Dis (2012) 1.72
Variations in the sequence and expression of the Plasmodium falciparum chloroquine resistance transporter (Pfcrt) and their relationship to chloroquine resistance in vitro. Mol Biochem Parasitol (2004) 1.71
Global epidemiology of tuberculosis. Semin Respir Crit Care Med (2013) 1.66
Integrating tuberculosis and HIV services in low- and middle-income countries: a systematic review. Trop Med Int Health (2012) 1.66
Lives saved by tuberculosis control and prospects for achieving the 2015 global target for reducing tuberculosis mortality. Bull World Health Organ (2011) 1.64
Tuberculosis and HIV interaction in sub-Saharan Africa: impact on patients and programmes; implications for policies. Trop Med Int Health (2005) 1.63
Tuberculosis comorbidity with communicable and non-communicable diseases: integrating health services and control efforts. Lancet Infect Dis (2013) 1.62
HIV, STIs, and sexual behaviors among men who have sex with men in Phnom Penh, Cambodia. AIDS Educ Prev (2004) 1.59
Global epidemiology of tuberculosis. Clin Chest Med (2005) 1.59
Screening of patients with tuberculosis for diabetes mellitus in China. Trop Med Int Health (2012) 1.58
Patient empowerment in tuberculosis control: reflecting on past documented experiences. Trop Med Int Health (2007) 1.51
Nutrition, diabetes and tuberculosis in the epidemiological transition. PLoS One (2011) 1.51
Assessing tuberculosis case fatality ratio: a meta-analysis. PLoS One (2011) 1.49
Antiretroviral therapy for tuberculosis control in nine African countries. Proc Natl Acad Sci U S A (2010) 1.48
New drugs for the treatment of tuberculosis: needs, challenges, promise, and prospects for the future. J Infect Dis (2012) 1.46
Public-private mix for DOTS implementation: what makes it work? Bull World Health Organ (2004) 1.46
The effect of tuberculosis on mortality in HIV positive people: a meta-analysis. PLoS One (2010) 1.46
Resources required for global tuberculosis control. Science (2002) 1.43
How human immunodeficiency virus voluntary testing can contribute to tuberculosis control. Bull World Health Organ (2003) 1.43
Tuberculosis elimination: theory and practice in Europe. Eur Respir J (2014) 1.42
Modernizing surveillance of antituberculosis drug resistance: from special surveys to routine testing. Clin Infect Dis (2011) 1.41
Hard gains through soft contracts: productive engagement of private providers in tuberculosis control. Bull World Health Organ (2006) 1.39
Global burden and epidemiology of tuberculosis. Clin Chest Med (2009) 1.35
What are the obstacles to generic substitution? An assessment of the behaviour of prescribers, patients and pharmacies during the first year of generic substitution in Sweden. Pharmacoepidemiol Drug Saf (2005) 1.32
Chronic diarrhea, hemorrhagic colitis, and hemolytic-uremic syndrome associated with HEp-2 adherent Escherichia coli in adults infected with human immunodeficiency virus in Bangui, Central African Republic. J Clin Microbiol (2002) 1.29
Screening patients with diabetes mellitus for tuberculosis in China. Trop Med Int Health (2012) 1.27
Reducing deaths from tuberculosis in antiretroviral treatment programmes in sub-Saharan Africa. AIDS (2012) 1.26
Tuberculosis control is crucial to achieve the MDGs. Lancet (2010) 1.22
Spatial pattern of private health care provision in Ujjain, India: a provider survey processed and analysed with a Geographical Information System. Health Policy (2004) 1.22
Stopping tuberculosis: time to turn urgent attention to hospitals. Int J Tuberc Lung Dis (2008) 1.22
A community-based tuberculosis program in Cambodia. JAMA (2004) 1.21
HIV and tuberculosis--science and implementation to turn the tide and reduce deaths. J Int AIDS Soc (2012) 1.21
Secondary dengue virus type 4 infections in Vietnam. Southeast Asian J Trop Med Public Health (2005) 1.16
Socio economic position in TB prevalence and access to services: results from a population prevalence survey and a facility-based survey in Bangladesh. PLoS One (2012) 1.15
Tuberculosis: still a social disease. Int J Tuberc Lung Dis (2011) 1.11
Global Fund financing of public-private mix approaches for delivery of tuberculosis care. Trop Med Int Health (2011) 1.11
Prevention, diagnosis, and treatment of tuberculosis in children and mothers: evidence for action for maternal, neonatal, and child health services. J Infect Dis (2012) 1.09
Stopping tuberculosis in the 21st century: goals and strategies. Respirology (2010) 1.08
Do policy changes in the pharmaceutical reimbursement schedule affect drug expenditures? Interrupted time series analysis of cost, volume and cost per volume trends in Sweden 1986-2002. Health Policy (2006) 1.05
The health workforce crisis in TB control: a report from high-burden countries. Hum Resour Health (2005) 1.04
Prevention of tuberculosis in people living with HIV. Clin Infect Dis (2010) 1.04
Multidrug-resistant tuberculosis in children: evidence from global surveillance. Eur Respir J (2012) 1.03
Active case-finding for TB in the community: time to act. Lancet (2010) 1.03
Implementing the global plan to stop TB, 2011-2015--optimizing allocations and the Global Fund's contribution: a scenario projections study. PLoS One (2012) 1.01
Tuberculosis and HIV in people who inject drugs: evidence for action for tuberculosis, HIV, prison and harm reduction services. Curr Opin HIV AIDS (2012) 1.00
Managing tuberculosis in people who use and inject illicit drugs. Bull World Health Organ (2013) 1.00
Reaching the global tuberculosis control targets in the Western Pacific Region. Bull World Health Organ (2007) 1.00
The research agenda for improving health policy, systems performance, and service delivery for tuberculosis control: a WHO perspective. Bull World Health Organ (2002) 0.98
Using the TIME model in Spectrum to estimate tuberculosis-HIV incidence and mortality. AIDS (2014) 0.97
PEPFAR support for the scaling up of collaborative TB/HIV activities. J Acquir Immune Defic Syndr (2012) 0.95
Chest radiography for tuberculosis screening is back on the agenda. Int J Tuberc Lung Dis (2012) 0.94
Using pooled budgets to integrate health and welfare services: a comparison of experiments in England and Sweden. Health Soc Care Community (2005) 0.93
Tuberculosis mortality in HIV-infected individuals: a cross-national systematic assessment. Clin Epidemiol (2011) 0.93
Treatment of tuberculosis. BMJ (2003) 0.92
Tuberculosis and air travel: WHO guidance in the era of drug-resistant TB. Travel Med Infect Dis (2007) 0.92
Global Tuberculosis Control: Toward the 2015 Targets and Beyond. Ann Intern Med (2015) 0.92
Limitations on human rights: are they justifiable to reduce the burden of TB in the era of MDR- and XDR-TB? Health Hum Rights (2008) 0.91
Feasibility of antenatal and late HIV testing in pregnant women in Phnom Penh Cambodia: the PERIKAM/ANRS1205 study. AIDS (2002) 0.91
Transforming the global tuberculosis response through effective engagement of civil society organizations: the role of the World Health Organization. Bull World Health Organ (2011) 0.90